Pet Drug Reports

Drugs by active ingredient

Drug · single active ingredient

Ursodiol: adverse event reports

All products with this active ingredient · not in an FDA-approved animal drug

749reports naming this ingredient, 1999–20260.1% of all reports · about 28 a year
94reports, 12 months to March 2026154 in the 12 months before
55.6%classed serious, as reportedof 737 reports stating it
15.5%record death or euthanasia, as reported116 reports
94.1%of reports concern dogs0.1% of all dog reports

Between October 1999 and March 2026 FDA received 749 adverse event reports listing a drug with ursodiol as the recorded active ingredient. It is not the active ingredient of an FDA-approved animal drug; it reaches animals through human-label or compounded products.

openFDA masks the brand and manufacturer in every report, so these figures describe the ingredient across all products and cannot be attributed to a brand.

In the 12 months to March 2026, 94 reports named it, down 39% from 154 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Over its whole reporting history that is about 28 reports a year and 0.1% of all 1,357,245 reports (0.1% of all dog reports). How many animals received it is not published, so a count says nothing about how often a problem occurs per dose.

The signs named most often are lethargy (22.4%), vomiting (20.7%) and elevated alanine aminotransferase (ALT) (17.8%). A report can list several signs, so shares add to more than 100%; 846 different terms appear across these reports.

94.1% of reports concern dogs. Not every report describes illness: 10.9% were filed wholly or partly as lack of expected effectiveness. Of reports that state seriousness, 55.6% were classed as serious, and 15.5% of all reports record a death or euthanasia as an outcome, as reported. FDA has not necessarily determined whether any drug played a part.

Monthly reports by species, five years

Dog404 · peak 19
Apr 2021: 8May 2021: 7Jun 2021: 6Jul 2021: 4Aug 2021: 5Sep 2021: 2Oct 2021: 3Nov 2021: 2Dec 2021: 2Jan 2022: 3Feb 2022: 5Mar 2022: 4Apr 2022: 4May 2022: 3Jun 2022: 1Jul 2022: 1Aug 2022: 7Sep 2022: 2Oct 2022: 5Nov 2022: 4Dec 2022: 6Jan 2023: 6Feb 2023: 2Mar 2023: 5Apr 2023: 10May 2023: 2Jun 2023: 5Jul 2023: 1Aug 2023: 4Sep 2023: 1Oct 2023: 10Nov 2023: 8Dec 2023: 4Jan 2024: 8Feb 2024: 13Mar 2024: 8Apr 2024: 7May 2024: 6Jun 2024: 10Jul 2024: 10Aug 2024: 16Sep 2024: 14Oct 2024: 18Nov 2024: 16Dec 2024: 15Jan 2025: 19Feb 2025: 10Mar 2025: 7Apr 2025: 9May 2025: 8Jun 2025: 8Jul 2025: 9Aug 2025: 5Sep 2025: 6Oct 2025: 4Nov 2025: 7Dec 2025: 8Jan 2026: 5Feb 2026: 12Mar 2026: 42022202320242025
Cat31 · peak 2
Aug 2021: 1Nov 2021: 1Feb 2022: 1Mar 2022: 1Aug 2022: 1Sep 2022: 1Oct 2022: 1Jul 2023: 1Aug 2023: 1Sep 2023: 2Nov 2023: 1Dec 2023: 1Jan 2024: 2Feb 2024: 1May 2024: 1Aug 2024: 1Oct 2024: 2Nov 2024: 1Dec 2024: 1Apr 2025: 1Jul 2025: 2Aug 2025: 2Sep 2025: 2Oct 2025: 1Mar 2026: 12022202320242025
Horse0 · peak 1
2022202320242025
Other0 · peak 1
2022202320242025

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

0751501999: 119992004: 22008: 120082012: 222013: 3920132014: 132015: 3020152016: 322017: 4120172018: 412019: 4320192020: 382021: 5220212022: 502023: 6420232024: 1502025: 10820252026: 22

2026 covers reports received through March 2026 only.

Signs listed in reports

share of ursodiol reports listing the termall dog reports

  1. Lethargy[unusually tired or inactive]22.4%168
  2. Vomiting20.7%155
  3. Elevated alanine aminotransferase (ALT)[a liver enzyme above the normal range]17.8%133
  4. Diarrhoea[diarrhea]15.5%116
  5. Elevated serum alkaline phosphatase (SAP)[a liver and bone enzyme above the normal range]11.7%88
  6. Death by euthanasia[the animal was euthanized]11.3%85
  7. Elevated total bilirubin[bilirubin above the normal range]10.1%76
  8. Anorexia[not eating]8.7%65
  9. Elevated serum alkaline phosphatase (ALP)[a liver and bone enzyme above the normal range]7.9%59
  10. Elevated gamma-glutamyl transferase (GGT)[a liver enzyme above the normal range]7.6%57
  11. Elevated blood urea nitrogen (BUN)[a kidney value above the normal range]7.5%56
  12. Other abnormal test result NOS[abnormal laboratory result, type not specified]7.2%54
  13. Lack of efficacy - NOS[the product did not have the expected effect]7.1%53
  14. Polydipsia[drinking more than usual]6.8%51
  15. Elevated liver enzymes[liver enzymes above the normal range]6%45
  16. Hyperkalaemia[high blood potassium]5.9%44
  17. Polyuria[passing more urine than usual]5.7%43
  18. Elevated creatinine[a kidney value above the normal range]5.2%39
  19. Shaking4.9%37
  20. Gall bladder & bile duct disorder NOS[NOS: not otherwise specified]4.3%32
  21. Icterus[jaundice (yellowing)]4.3%32
  22. Proteinuria[protein in the urine]4.3%32
  23. Death4.1%31
  24. Underdose[less than the labelled amount was given]4%30
  25. Leucocytosis NOS[high white blood cell count]3.9%29

Top 30 of 846 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Outcome recorded in the report

Recovered/Normal18.4%138
Recovered with Sequela1.7%13
Ongoing33.8%253
Died4.3%32
Euthanized11.2%84
Outcome Unknown30%225

What kind of report it was

Safety issue88.1%660
Lack of expected effectiveness3.7%28
Both safety and lack of expected effectiveness7.2%54
Manufacturing or product defect0.9%7
Other0%0

Coloured bar: reports naming ursodiol. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Species

Dog94.1%705
Cat5.7%43
Other0.1%1

Single-breed animals

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Age of the animal

Under 1 year0%0
1 to 3 years2.5%19
4 to 7 years8.8%66
8 to 11 years37.1%278
12 years and over50.3%377
Age not given1.2%9

Weight of the animal

Under 5 kg (11 lb)17.5%131
5 to 9.9 kg (11–22 lb)29.6%222
10 to 24.9 kg (22–55 lb)27.5%206
25 to 44.9 kg (55–99 lb)21.9%164
45 kg and over (99 lb+)1.2%9
Weight not given2.3%17

Route of administration stated in reports: oral (439), other (2), intravenous (1).

In context

MeasureUrsodiolAll dog reportsAll reports
Reports749985,6751,357,245
Share of that pool's reports naming this drug—0.1%0.1%
Classed serious, of reports stating it55.6%38.3%38.6%
Death or euthanasia recorded, per 1,000 reports154.95563.8
Filed as lack of expected effectiveness (wholly or partly)10.9%—23%
Top term, share of reportsLethargy 22.4%7.9%—

This set accounts for 100% of all reports naming ursodiol, so no separate ingredient column is shown. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

FDA-approved products (Green Book)

Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 1 Oct 2026; nothing on this page says which of these products, if any, a report concerned.

The Green Book lists no approved animal drug with these ingredients. Reports reach FDA for human-label and compounded drugs that veterinarians prescribe.

Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).

Questions about ursodiol reports

How many adverse event reports has FDA received for ursodiol?

749 reports record a drug with ursodiol as its active ingredient in the openFDA release of 28 Sep 2026, covering reports received through March 2026. 94 of them arrived in the latest 12 months.

Which brand do these reports concern?

That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

What signs are reported most often?

lethargy (22.4%), vomiting (20.7%), elevated alanine aminotransferase (ALT) (17.8%), diarrhoea (15.5%) and elevated serum alkaline phosphatase (SAP) (11.7%). These are the coded terms listed in reports; several can appear in one report, and a term's presence is not a finding that the drug was responsible.

Which species and breeds appear in these reports?

dog (94.1%), cat (5.7%) and other (0.1%). Among single-breed animals the most frequent labels are Labrador Retriever, Chihuahua, Domestic Shorthair and Shih Tzu; popular breeds appear often in any drug's reports because there are more of them.

Are reports rising?

94 reports in the 12 months to March 2026, down 39% from 154 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Counts also move with sales, publicity and time on the market.

Do these reports show that ursodiol harms pets?

Report counts cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." FDA also notes that commonly used products may have more reports simply because more animals receive them.

Are these the side effects of ursodiol?

They are signs listed in reports, not an established list of side effects. The adverse reactions observed in studies are printed on each product's FDA-approved label, which a veterinarian can go through with you. This page is a record of what was reported to FDA.

How do I report a problem with an animal drug?

FDA asks owners and veterinarians to call the drug company first (the number is on the label); companies must pass reports to FDA. Reports can also go directly to FDA on Form FDA 1932a. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.